Previous studies on the lymphocyte subset counts showed close relations between (i) CD4+ and CD8+ T cell counts and (ii) disease severity and clinical outcome, and suggested that the CD4+ and CD8+ T cell counts in patients with COVID-19 could be good biomarkers of COVID-19 activity [21,22]. The gene discussed is CD8A; the disease is COVID-19.